

Mihajlo Michael Jakovljevic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6779192/publications.pdf>

Version: 2024-02-01

219
papers

90,456
citations

15504

65
h-index

1599

216
g-index

241
all docs

241
docs citations

241
times ranked

109277
citing authors

#	ARTICLE	IF	CITATIONS
1	Disempowered Mothers Have Undernourished Children: How Strong Is the Intrinsic Agency?. Frontiers in Public Health, 2022, 10, 817717.	2.7	4
2	Predictors of loss due to pharmaceutical fraud: evidence from the U.S.. Cost Effectiveness and Resource Allocation, 2022, 20, 6.	1.5	5
3	Prevalence of COVID-19 Pandemic, Self-Esteem and Its Effect on Depression Among University Students in Saudi Arabia. Frontiers in Public Health, 2022, 10, 836688.	2.7	12
4	A Global Assessment of Sustainable Development: Integrating Socioeconomic, Resource and Environmental Dimensions. Frontiers in Energy Research, 2022, 10, .	2.3	9
5	Future health spending forecast in leading emerging BRICS markets in 2030: health policy implications. Health Research Policy and Systems, 2022, 20, 23.	2.8	45
6	How China controls the Covid-19 epidemic through public health expenditure and policy?. Journal of Medical Economics, 2022, 25, 437-449.	2.1	31
7	Global, regional, and national burden of colorectal cancer and its risk factors, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Gastroenterology and Hepatology, 2022, 7, 627-647.	8.1	177
8	Editorial: Emerging Marketsâ€™ Health and Pharmaceutical Sectors at the Dawn of a Potential Global Financial Crisis of early 2020s. Frontiers in Pharmacology, 2022, 13, 907612.	3.5	3
9	The burden of injury in Central, Eastern, and Western European sub-region: a systematic analysis from the Global Burden of Disease 2019 Study. Archives of Public Health, 2022, 80, 142.	2.4	9
10	Editorial: Fraud and Corruption in Healthcare. Frontiers in Public Health, 2022, 10, .	2.7	2
11	Global article collection: essential reads from around the world. Journal of Medical Economics, 2022, 25, 864-869.	2.1	1
12	Systematic Review of Existing Stroke Guidelines: Case for a Change. BioMed Research International, 2022, 2022, 1-11.	1.9	1
13	Gap analysis in manufacturing, innovation and marketing of medical devices in the Asia-Pacific region. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 1043-1050.	1.4	12
14	Mapping routine measles vaccination in low- and middle-income countries. Nature, 2021, 589, 415-419.	27.8	71
15	Aging and Global Health. , 2021, , 73-102.		6
16	Mapping subnational HIV mortality in six Latin American countries with incomplete vital registration systems. BMC Medicine, 2021, 19, 4.	5.5	78
17	Demographic forecasting of population aging in Greece and Cyprus: one big challenge for the Mediterranean health and social system long-term sustainability. Health Research Policy and Systems, 2021, 19, 21.	2.8	24
18	Cost Analysis of Health Examination Screening Program for Ischemic Heart Disease in Active-Duty Military Personnel in the Middle-Income Country. Frontiers in Public Health, 2021, 9, 634778.	2.7	5

#	ARTICLE	IF	CITATIONS
19	Public Health Policy of India and COVID-19: Diagnosis and Prognosis of the Combating Response. Sustainability, 2021, 13, 3415.	3.2	20
20	Highlighting the Role of Universally Available and Innate Immune Cell Counts in Acute Ischemic Stroke: A Scoping Review. Sustainability, 2021, 13, 4069.	3.2	1
21	Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990â€“2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Public Health, The, 2021, 6, e482-e499.	10.0	38
22	Subnational mapping of HIV incidence and mortality among individuals aged 15â€“49 years in sub-Saharan Africa, 2000â€“18: a modelling study. Lancet HIV, the, 2021, 8, e363-e375.	4.7	32
23	Analysis and Forecasting Incidence, Intensive Care Unit Admissions, and Projected Mortality Attributable to COVID-19 in Portugal, the UK, Germany, Italy, and France: Predictions for 4 Weeks Ahead. Bioengineering, 2021, 8, 84.	3.5	12
24	The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. Frontiers in Public Health, 2021, 9, 671961.	2.7	22
25	Editorial: Accelerated Globalization and Its Impact to the World's Health Care Achievement. Frontiers in Public Health, 2021, 9, 690239.	2.7	2
26	Editorial: NCDs â€“ Core Challenge of Modern Day Health Care Establishments. Frontiers in Public Health, 2021, 9, 692926.	2.7	9
27	Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990â€“2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet, The, 2021, 397, 2337-2360.	13.7	609
28	Happiness: A Novel Outcome Measure in Stroke?. Therapeutics and Clinical Risk Management, 2021, Volume 17, 747-754.	2.0	0
29	COVID-19 Pandemic: An Opportunity for Universal Health Coverage. Frontiers in Public Health, 2021, 9, 673542.	2.7	24
30	Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future. Current Medical Research and Opinion, 2021, 37, 1529-1545.	1.9	13
31	COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: Indiaâ€™s Role at the WTO Platform. BioMed Research International, 2021, 2021, 1-8.	1.9	33
32	Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990â€“2050. Lancet, The, 2021, 398, 1317-1343.	13.7	79
33	Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. BioMed Research International, 2021, 2021, 1-16.	1.9	7
34	Sustainability Challenge of Eastern Europeâ€™ Historical Legacy, Belt and Road Initiative, Population Aging and Migration. Sustainability, 2021, 13, 11038.	3.2	25
35	Global, regional, and national mortality among young people aged 10â€“24 years, 1950â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2021, 398, 1593-1618.	13.7	92
36	A Proactive Approach to Identify the Exposure Risk to COVID-19: Validation of the Pandemic Risk Exposure Measurement (PREM) Model Using Real-World Data. Risk Management and Healthcare Policy, 2021, Volume 14, 4775-4787.	2.5	13

#	ARTICLE	IF	CITATIONS
37	Editorial: Universal Health Coverage: The Long Road Ahead for Low- and Middle-Income Regions. <i>Frontiers in Public Health</i> , 2021, 9, 746651.	2.7	3
38	Therapeutic innovations: the future of health economics and outcomes research – increasing role of the Asia-Pacific. <i>Journal of Medical Economics</i> , 2021, 24, (i)-(iii).	2.1	9
39	Asian innovation in pharmaceutical and medical device industry – beyond tomorrow. <i>Journal of Medical Economics</i> , 2021, 24, 42-50.	2.1	31
40	The Global South political economy of health financing and spending landscape – history and presence. <i>Journal of Medical Economics</i> , 2021, 24, 25-33.	2.1	72
41	How Fast Are the Asian Countries Progressing Toward Green Economy? Implications for Public Health. <i>Frontiers in Public Health</i> , 2021, 9, 753338.	2.7	6
42	Editorial: Health Financing and Spending in Low- and Middle-Income Countries. <i>Frontiers in Public Health</i> , 2021, 9, 800333.	2.7	2
43	Mapping child growth failure across low- and middle-income countries. <i>Nature</i> , 2020, 577, 231-234.	27.8	128
44	Mapping disparities in education across low- and middle-income countries. <i>Nature</i> , 2020, 577, 235-238.	27.8	58
45	Gross Domestic Product and Health Expenditure Growth in Balkan and East European Countries – Three-Decade Horizon. <i>Frontiers in Public Health</i> , 2020, 8, 492.	2.7	19
46	Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1204-1222.	13.7	7,664
47	Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249.	13.7	3,928
48	Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1135-1159.	13.7	335
49	Organizational measures aiming to combat COVID-19 in the Russian Federation: the first experience. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 571-576.	1.4	32
50	Aging and Global Health. , 2020, , 1-30.		1
51	Real GDP growth rates and healthcare spending – comparison between the G7 and the EM7 countries. <i>Globalization and Health</i> , 2020, 16, 64.	4.9	109
52	Fraudster™s and victims™ profiles and loss predictors™ hierarchy in the mental healthcare industry in the US. <i>Journal of Medical Economics</i> , 2020, 23, 1111-1122.	2.1	8
53	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17. <i>The Lancet Global Health</i> , 2020, 8, e1038-e1060.	6.3	23
54	<p>>Predictors of (in)efficiencies of Healthcare Expenditure Among the Leading Asian Economies – Comparison of OECD and Non-OECD Nations</p>>. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 2261-2280.	2.5	103

#	ARTICLE	IF	CITATIONS
55	<p>A Country Pandemic Risk Exposure Measurement Model</p>. Risk Management and Healthcare Policy, 2020, Volume 13, 2067-2077.	2.5	28
56	Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study. Injury Prevention, 2020, 26, i125-i153.	2.4	44
57	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1250-1284.	13.7	330
58	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000â€“17. The Lancet Global Health, 2020, 8, e1162-e1185.	6.3	91
59	Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i96-i114.	2.4	103
60	Corona-Triggered Global Macroeconomic Crisis of the Early 2020s. International Journal of Environmental Research and Public Health, 2020, 17, 9404.	2.6	28
61	Prevalence and attributable health burden of chronic respiratory diseases, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respiratory Medicine,the, 2020, 8, 585-596.	10.7	1,049
62	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000â€“17: analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 1779-1801.	13.7	72
63	Changes in disease burden in Poland between 1990â€“2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017. PLoS ONE, 2020, 15, e0226766.	2.5	33
64	Promises and Hurdles of Medical Tourism Development in the Russian Federation. Frontiers in Psychology, 2020, 11, 1380.	2.1	9
65	The Evaluation of Antibiotic Consumption at the Inpatient Level in Kazakhstan from 2011 to 2018. Antibiotics, 2020, 9, 57.	3.7	17
66	Alcohol Consumption among the Elderly Citizens in Hungary and Serbiaâ€“Comparative Assessment. International Journal of Environmental Research and Public Health, 2020, 17, 1289.	2.6	10
67	A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries. Frontiers in Public Health, 2020, 8, 29.	2.7	16
68	Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. Lancet, The, 2020, 396, 693-724.	13.7	87
69	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. Nature Medicine, 2020, 26, 750-759.	30.7	47
70	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i12-i26.	2.4	44
71	Morbidity and mortality from road injuries: results from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i46-i56.	2.4	86
72	Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016. Occupational and Environmental Medicine, 2020, 77, 151-159.	2.8	64

#	ARTICLE	IF	CITATIONS
73	Cost-effectiveness and resource allocation (CERA) 18 years of evolution: maturity of adulthood and promise beyond tomorrow. Cost Effectiveness and Resource Allocation, 2020, 18, 15.	1.5	36
74	Sanitary and Hygienic Aspects of the COVID-19 Self-isolation. Open Public Health Journal, 2020, 13, 734-738.	0.4	15
75	BRICs Nations Growing Impact on the Global Health Sector. Vestnik MGIMO-Universiteta, 2020, 12, 150-166.	0.3	2
76	The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2019, 4, 913-933.	8.1	259
77	The impact of health expenditures on public health in BRICS nations. Journal of Sport and Health Science, 2019, 8, 516-519.	6.5	79
78	Situation, Impacts, and Future Challenges of Tobacco Control Policies for Youth: An Explorative Systematic Policy Review. Frontiers in Pharmacology, 2019, 10, 981.	3.5	20
79	Underlying Differences in Health Spending Within the World Health Organisation Europe Region—Comparing EU15, EU Post-2004, CIS, EU Candidate, and CARIN FNET Countries. International Journal of Environmental Research and Public Health, 2019, 16, 3043.	2.6	42
80	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. JAMA Oncology, 2019, 5, 1749.	7.1	1,691
81	Analysis of the Financing of Russian Health Care over the Past 100 Years. International Journal of Environmental Research and Public Health, 2019, 16, 1848.	2.6	25
82	Medical Cost of Colorectal Cancer Services in Serbia Between 2014 and 2017: National Data Report. Frontiers in Pharmacology, 2019, 10, 526.	3.5	4
83	Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050. Lancet, The, 2019, 393, 2233-2260.	13.7	283
84	Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	10.2	2,625
85	Comparative financing analysis and political economy of noncommunicable diseases. Journal of Medical Economics, 2019, 22, 722-727.	2.1	140
86	Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 376-393.	10.2	359
87	Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016. BMJ: British Medical Journal, 2019, 364, l94.	2.3	558
88	Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 357-375.	10.2	526
89	Dynamics of Health Care Financing and Spending in Serbia in the XXI Century. Frontiers in Public Health, 2019, 7, 381.	2.7	3
90	The Impact of the Socio-Demographic Characteristics of Complementary and Alternative Medicine Users in Serbia on OTC Drug Consumption. Frontiers in Public Health, 2019, 7, 303.	2.7	2

#	ARTICLE	IF	CITATIONS
91	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 56-87.	10.2	1,064
92	Structural Factors Responsible for Universal Health Coverage in Low- and Middle-Income Countries: Results From 118 Countries. <i>Frontiers in Public Health</i> , 2019, 7, 414.	2.7	56
93	Local Anesthesia in Pediatric Patients â€“ a Review of Current and Alternative Methods, Devices and Techniques. <i>Folia Medica</i> , 2018, 60, 381-388.	0.5	9
94	Access to orphan drugs â€“ comparison across Balkan countries. <i>Health Policy</i> , 2018, 122, 583-589.	3.0	20
95	Caffeine consumption patterns and determinants among adolescents in Serbia. <i>International Journal of Adolescent Medicine and Health</i> , 2018, 30, .	1.3	3
96	Burden of cancer in the Eastern Mediterranean Region, 2005â€“2015: findings from the Global Burden of Disease 2015 Study. <i>International Journal of Public Health</i> , 2018, 63, 151-164.	2.3	48
97	Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 47-61.	2.3	9
98	The burden of mental disorders in the Eastern Mediterranean region, 1990â€“2015: findings from the global burden of disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 25-37.	2.3	43
99	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1684-1735.	13.7	716
100	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1736-1788.	13.7	4,989
101	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1923-1994.	13.7	3,269
102	Population and fertility by age and sex for 195 countries and territories, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1995-2051.	13.7	294
103	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1789-1858.	13.7	8,569
104	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 2091-2138.	13.7	335
105	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1859-1922.	13.7	2,123
106	Cold War Legacy in Public and Private Health Spending in Europe. <i>Frontiers in Public Health</i> , 2018, 6, 215.	2.7	17
107	Editorial: Challenges of Pharmacoeconomics in Global Health Arena. <i>Frontiers in Public Health</i> , 2018, 6, 368.	2.7	3
108	Editorial: Global Population Aging - Health Care, Social and Economic Consequences. <i>Frontiers in Public Health</i> , 2018, 6, 335.	2.7	73

#	ARTICLE	IF	CITATIONS
109	The Influence of Universal Health Coverage on Life Expectancy at Birth (LEAB) and Healthy Life Expectancy (HALE): A Multi-Country Cross-Sectional Study. <i>Frontiers in Pharmacology</i> , 2018, 9, 960.	3.5	62
110	Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1191-1210.	9.1	1,084
111	Global Burden of Multiple Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1221.	7.1	398
112	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2018, 391, 2236-2271.	13.7	638
113	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. <i>JAMA Oncology</i> , 2018, 4, 1553.	7.1	1,260
114	High Out-of-Pocket Health Spending in Countries With a Mediterranean Connection. <i>Frontiers in Public Health</i> , 2018, 6, 145.	2.7	13
115	Population aging and migration â€“ history and UN forecasts in the EU-28 and its east and south near neighborhood â€“ one century perspective 1950â€“2050. <i>Globalization and Health</i> , 2018, 14, 30.	4.9	39
116	Alcohol use and burden for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2018, 392, 1015-1035.	13.7	2,005
117	High Inequalities Associated With Socioeconomic Deprivation in Cardiovascular Disease Burden and Antihypertensive Medication in Hungary. <i>Frontiers in Pharmacology</i> , 2018, 9, 839.	3.5	17
118	Antibiotic Resistance in Syria: A Local Problem Turns Into a Global Threat. <i>Frontiers in Public Health</i> , 2018, 6, 212.	2.7	35
119	Global Mortality From Firearms, 1990-2016. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 792.	7.4	189
120	The burden of disease in Greece, health loss, risk factors, and health financing, 2000â€“16: an analysis of the Global Burden of Disease Study 2016. <i>Lancet Public Health</i> , The, 2018, 3, e395-e406.	10.0	37
121	Future and potential spending on health 2015â€“40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. <i>Lancet</i> , The, 2017, 389, 2005-2030.	13.7	163
122	Evolution and patterns of global health financing 1995â€“2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. <i>Lancet</i> , The, 2017, 389, 1981-2004.	13.7	204
123	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. <i>JAMA Oncology</i> , 2017, 3, 524.	7.1	4,254
124	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet</i> , The, 2017, 390, 231-266.	13.7	480
125	Pharmaceutical expenditure dynamics in the Balkan countries. <i>Journal of Medical Economics</i> , 2017, 20, 1013-1017.	2.1	10
126	Child and Adolescent Health From 1990 to 2015. <i>JAMA Pediatrics</i> , 2017, 171, 573.	6.2	306

#	ARTICLE	IF	CITATIONS
127	Within the triangle of healthcare legacies: comparing the performance of South-Eastern European health systems. <i>Journal of Medical Economics</i> , 2017, 20, 483-492.	2.1	29
128	Transposition and implementation of EU rare disease policy in Eastern Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 557-566.	1.4	8
129	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1084-1150.	13.7	573
130	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1260-1344.	13.7	1,589
131	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1151-1210.	13.7	3,565
132	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1211-1259.	13.7	5,578
133	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1345-1422.	13.7	1,879
134	Global, regional, and national burden of neurological disorders during 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Neurology</i> , The, 2017, 16, 877-897.	10.2	1,521
135	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1423-1459.	13.7	284
136	Global, Regional, and National Levels of Maternal Mortality, 1990â€“2015: A Systematic Analysis for the Global Burden of Disease Study 2015. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 11-13.	0.4	41
137	Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 691-706.	10.7	1,672
138	Evolving Health Expenditure Landscape of the BRICS Nations and Projections to 2025. <i>Health Economics (United Kingdom)</i> , 2017, 26, 844-852.	1.7	141
139	Commentary: Do health care workforce, population, and service provision significantly contribute to the total health expenditure? An econometric analysis of Serbia. <i>Frontiers in Pharmacology</i> , 2017, 8, 33.	3.5	3
140	Satisfaction with Health Services among the Citizens of Serbia. <i>Frontiers in Pharmacology</i> , 2017, 8, 50.	3.5	12
141	Alcohol Beverage Household Expenditure, Taxation and Government Revenues in Broader European WHO Region. <i>Frontiers in Pharmacology</i> , 2017, 8, 303.	3.5	8
142	Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies. <i>Frontiers in Pharmacology</i> , 2017, 8, 662.	3.5	8
143	Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countriesâ€”Forecasts to 2020. <i>Frontiers in Public Health</i> , 2017, 5, 23.	2.7	23
144	Growth of Global Publishing Output of Health Economics in the Twenty-First Century: A Bibliographic Insight. <i>Frontiers in Public Health</i> , 2017, 5, 211.	2.7	11

#	ARTICLE	IF	CITATIONS
145	Population ageing alongside health care spending growth. Srpski Arhiv Za Celokupno Lekarstvo, 2017, 145, 534-539.	0.2	20
146	RESILIENCE, PSYCHIATRY AND RELIGION FROM PUBLIC AND GLOBAL MENTAL HEALTH PERSPECTIVE Dialogue and Cooperation in the Search for Humanistic Self, Compassionate Society and Empathic Civilization. Psychiatria Danubina, 2017, 29, 238-244.	0.4	21
147	Do Health Reforms Impact Cost Consciousness of Health Care Professionals? Results from a Nation-Wide Survey in the Balkans. Balkan Medical Journal, 2016, 33, 8-17.	0.8	48
148	The New and Old Europe: East-West Split in Pharmaceutical Spending. Frontiers in Pharmacology, 2016, 7, 18.	3.5	39
149	Growth of Global Health Spending Share in Low and Middle Income Countries. Frontiers in Pharmacology, 2016, 7, 21.	3.5	99
150	Commentary: Patient Cost Sharing and Medical Expenditures for the Elderly. Frontiers in Pharmacology, 2016, 7, 73.	3.5	10
151	Self-Assessed Health and Socioeconomic Inequalities in Serbia: Data from 2013 National Health Survey. Frontiers in Pharmacology, 2016, 7, 140.	3.5	16
152	Long Term Dental Work Force Build-Up and DMFT-12 Improvement in the European Region. Frontiers in Physiology, 2016, 7, 48.	2.8	7
153	Editorial: Health Care Financing and Affordability in the Emerging Global Markets. Frontiers in Public Health, 2016, 4, 2.	2.7	47
154	Health Economics at the Crossroads of Centuries – From the Past to the Future. Frontiers in Public Health, 2016, 4, 115.	2.7	75
155	Commentary: Implementing Pro-Poor Universal Health Coverage. Frontiers in Public Health, 2016, 4, 186.	2.7	2
156	Capitation-Based Financing Hampers the Provision of Preventive Services in Primary Health Care. Frontiers in Public Health, 2016, 4, 200.	2.7	23
157	Review of Diagnosis-Related Group-Based Financing of Hospital Care. Health Services Research and Managerial Epidemiology, 2016, 3, 233339281664789.	0.9	64
158	Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1775-1812.	13.7	740
159	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	13.7	4,934
160	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	13.7	5,298
161	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	13.7	4,203
162	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	13.7	413

#	ARTICLE	IF	CITATIONS
163	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2015: the Global Burden of Disease Study 2015. <i>Lancet HIV</i> , 2016, 3, e361-e387.	4.7	461
164	CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 439-445.	1.9	13
165	Comparison of historical medical spending patterns among the BRICS and G7. <i>Journal of Medical Economics</i> , 2016, 19, 70-76.	2.1	76
166	Life expectancy and health expenditure evolution in Eastern Europeâ€“DiD and DEA analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 537-546.	1.4	81
167	Can Didactic Continuing Education Improve Clinical Decision Making and Reduce Cost of Quality? Evidence From a Case Study. <i>Journal of Continuing Education in the Health Professions</i> , 2015, 35, 109-118.	1.3	15
168	Community-acquired pneumonia: economics of inpatient medical care vis-Ã-vis clinical severity,. <i>Jornal Brasileiro De Pneumologia</i> , 2015, 41, 48-57.	0.7	27
169	When cure becomes an illnessâ€“abuse of addictive prescription medicines. <i>Frontiers in Pharmacology</i> , 2015, 6, 193.	3.5	21
170	Regulatory Issues Surrounding Audit of Electronic Cigarette Charge Composition. <i>Frontiers in Psychiatry</i> , 2015, 6, 133.	2.6	4
171	Growing Burden of Non-Communicable Diseases in the Emerging Health Markets: The Case of BRICS. <i>Frontiers in Public Health</i> , 2015, 3, 65.	2.7	109
172	BRICâ€™s Growing Share of Global Health Spending and Their Diverging Pathways. <i>Frontiers in Public Health</i> , 2015, 3, 135.	2.7	58
173	Improvements in Neonatal and Childhood Medical Care â€“ Perspective from the Balkans. <i>Frontiers in Public Health</i> , 2015, 3, 206.	2.7	2
174	Budget Impact of Publicly Reimbursed Prescription Medicines in the Republic of Srpska. <i>Frontiers in Public Health</i> , 2015, 3, 213.	2.7	16
175	Macroeconomic Policy Impact On Oncology-Related Public Expenditure In An Emerging European Market â€“ Signs Of Early Recovery. <i>Serbian Journal of Experimental and Clinical Research</i> , 2015, 16, 43-50.	0.1	9
176	Evolution of the Serbian pharmaceutical market alongside socioeconomic transition. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 521-530.	1.4	44
177	Intentional Self-Poisonings and Unintentional Poisonings of Adolescents With Nonfatal Outcomes. <i>Journal of Child and Adolescent Substance Abuse</i> , 2015, 24, 12-18.	0.5	3
178	End-of-life costs of medical care for advanced stage cancer patients. <i>Vojnosanitetski Pregled</i> , 2015, 72, 334-341.	0.2	31
179	Five-year survival and costs of care in metastatic colorectal cancer: conventional versus monoclonal antibody-based treatment protocols. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 963-970.	2.4	12
180	Radiation therapy remains the key cost driver of oncology inpatient treatment. <i>Journal of Medical Economics</i> , 2015, 18, 29-36.	2.1	28

#	ARTICLE	IF	CITATIONS
181	Cost-effectiveness of depressive episode pharmacological treatment. Hospital Pharmacology, 2015, 2, 235-245.	0.3	6
182	Hospital oncology costs among the cohort of elderly in an aging South-Eastern European nation. Farmeconomia E Percorsi Terapeutici, 2015, 16, 3-5.	0.1	3
183	Cost differentials of dental outpatient care across clinical dentistry branches. Farmeconomia E Percorsi Terapeutici, 2015, 16, 25-32.	0.1	3
184	The aging of Europe. The unexplored potential. Farmeconomia E Percorsi Terapeutici, 2015, 16, 89-92.	0.1	18
185	Direct costs of treating community-acquired pneumonia do not necessarily correlate with clinical severity. , 2015, , .		0
186	Targeted immunotherapies overtaking emerging oncology market value based growth. Journal of B U on, 2015, 20, 350-1.	0.4	3
187	A comment on the article: StoÅiÄ S, KaranoviÄ N. Health care economics in Serbia: current problems and changes. Vojnosanit Pregl 2014; 71(11): 1055-1061. Vojnosanitetski Pregled, 2015, 72, 203-5.	0.2	4
188	The Key Role of the Leading Emerging Bric Markets in the Future of Global Health Care. Serbian Journal of Experimental and Clinical Research, 2014, 15, 139-143.	0.1	31
189	Contemporary generic market in Japan â€“ key conditions to successful evolution. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 181-194.	1.4	41
190	Craniocerebral injuries in traffic accidents with fatal outcomes. Australian Journal of Forensic Sciences, 2014, 46, 180-193.	1.2	4
191	Health Financing Constrained by Population Aging - An Opportunity to Learn from Japanese Experience / Finansiranje Zdravstvene ZaÅtite U Uslovima Åtarenja Popualcije - Prilika Da UÅimo Na Japanskom Iskustvu. Serbian Journal of Experimental and Clinical Research, 2014, 15, 175-181.	0.1	62
192	Accessibility and Affordability of Alcohol Dependency Medical Care in Serbia. Frontiers in Psychiatry, 2014, 5, 192.	2.6	15
193	LAT Software Induced Savings on Medical Costs of Alcohol Addicts' Care - Results from a Matched-Pairs Case-Control Study. PLoS ONE, 2014, 9, e111931.	2.5	15
194	Health expenditure dynamics in Serbia 1995-2012. Hospital Pharmacology, 2014, 1, 180-183.	0.3	16
195	10.5937/mckg48-5071 = Recent developments in the world's leading generic markets. Medicinski Casopis, 2014, 48, 140-142.	0.1	3
196	The key role of the leading emerging BRIC markets in the future of global health care. Serbian Journal of Experimental and Clinical Research, 2014, 15, 139-143.	0.1	11
197	Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. Farmeconomia E Percorsi Terapeutici, 2014, 15, 27-32.	0.1	24
198	Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma. Journal of B U on, 2014, 19, 1111-20.	0.4	13

#	ARTICLE	IF	CITATIONS
199	Radiology Services Costs and Utilization Patterns Estimates in Southeastern Europeâ€”A Retrospective Analysis from Serbia. <i>Value in Health Regional Issues</i> , 2013, 2, 218-225.	1.2	31
200	Cross-sectional survey on complementary and alternative medicine awareness among health care professionals and students using CHBQ questionnaire in a Balkan country. <i>Chinese Journal of Integrative Medicine</i> , 2013, 19, 650-655.	1.6	13
201	Resource allocation strategies in Southeastern European health policy. <i>European Journal of Health Economics</i> , 2013, 14, 153-159.	2.8	107
202	Serbian and Austrian Alcohol-Dependent Patients: A Comparison of Two Samples Regarding Therapeutically Relevant Clinical Features. <i>Alcohol and Alcoholism</i> , 2013, 48, 505-508.	1.6	19
203	Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2Î± + Ribavirine Treated Chronic Hepatitis C Patients. <i>Hepatitis Monthly</i> , 2013, 13, e6750.	0.2	11
204	Direct medical costs of COPD diagnosis and treatment, Eastern vs Western European country â€” examples of Serbia and Belgium. <i>Farneconomia E Percorsi Terapeutici</i> , 2013, 14, 161-168.	0.1	15
205	Impact of imaging diagnostics on the budget—are we spending too much?. <i>Vojnosanitetski Pregled</i> , 2013, 70, 709-11.	0.2	15
206	A ten-year study of depressive symptoms in Serbian medical students. <i>Acta Clinica Croatica</i> , 2013, 52, 157-63.	0.2	10
207	Validation of a patient satisfaction questionnaire in primary health care. <i>Public Health</i> , 2012, 126, 710-718.	2.9	35
208	Blood alcohol concentration impact on the traffic accident rates with fatal outcome. <i>Medicinski Casopis</i> , 2012, 46, 160-167.	0.1	1
209	Role of anticonvulsant therapeutic drug monitoring in improving clinical outcomes: An example of 12 adult epilepsy patients. <i>Serbian Journal of Experimental and Clinical Research</i> , 2012, 13, 68-71.	0.1	0
210	Cost of illness of community-acquired pneumonia. Review of the literature and possible strategies in the Serbian health care setting. <i>Farneconomia E Percorsi Terapeutici</i> , 2012, 13, 133-139.	0.1	4
211	Inpatient Detoxification Procedure and Facilities: Financing Considerations from an Eastern European Perspective. <i>Alcohol and Alcoholism</i> , 2011, 46, 364-365.	1.6	17
212	Economics of cancer related medical care: Worldwide estimates and available domestic evidence. <i>Archive of Oncology</i> , 2011, 19, 59-63.	0.2	11
213	Current efforts and proposals to reduce healthcare costs in Serbia. <i>Serbian Journal of Experimental and Clinical Research</i> , 2011, 12, 161-163.	0.1	40
214	A Nonlinear Mixed Effects Modelling Analysis of Topiramate Pharmacokinetics in Patients with Epilepsy. <i>Biological and Pharmaceutical Bulletin</i> , 2010, 33, 1176-1182.	1.4	21
215	Inverse correlation of valproic acid serum concentrations and quality of life in adolescents with epilepsy. <i>Epilepsy Research</i> , 2008, 80, 180-183.	1.6	12
216	Cost-Effectiveness of Ritodrine and Fenoterol for Treatment of Preterm Labor in a Lowâ€”Middle-Income Country: A Case Study. <i>Value in Health</i> , 2008, 11, 149-153.	0.3	17

#	ARTICLE	IF	CITATIONS
217	Effect of exogenous glutamate and Na ⁺ -Methylaspartic acid on spontaneous activity of isolated human ureter. International Journal of Urology, 2007, 14, 833-837.	1.0	9
218	Inhibitory effects of selected antiepileptics on spontaneous motility of isolated human oviducts. European Journal of Clinical Pharmacology, 2006, 62, 707-712.	1.9	5
219	Environmental Pollution Liability Insurance of Health Risk and Corporate Environmental Performance: Evidence From China. Frontiers in Public Health, 0, 10, .	2.7	2